Table 2 Prognostic factors for overall survival (OS) in colorectal cancer.
From: Tumor-suppressive role of Smad ubiquitination regulatory factor 2 in patients with colorectal cancer
Prognostic factors | n | 5-year OS rate (%) | Univariate P value | Multivariate HR (95% CI) | P value |
|---|---|---|---|---|---|
Age at primary surgery, < 65/ ≥ 65 | 44/22 | 54.6/60.8 | 0.7742 |  |  |
Sex, Male/Female | 44/22 | 53.8/68.2 | 0.7217 | Â | Â |
Site of primary tumor, Colon/Rectum | 40/26 | 74.7/34.6 | 0.0022 | 0.30 (0.129–0.647) | 0.0019 |
Site of primary tumor, Right/Left | 19/47 | 78.6/51.1 | 0.0486 | 0.93 (0.339–2.541) | 0.8864 |
CEA < 5/ ≥ 5 | 18/48 | 65.5/56.3 | 0.1631 |  |  |
CA19-9 < 37/ ≥ 37 | 43/23 | 64.5/47.8 | 0.2476 |  |  |
Degree of differentiation, tub, pap/por, muc | 62/4 | 57.6/75.0 | 0.9649 | Â | Â |
ly, 0–1/2–3 | 55/11 | 56.4/71.6 | 0.9228 |  |  |
v, 0–1/2–3 | 31/35 | 71.0/47.5 | 0.1033 |  |  |
T stage (8th edition), 1–3/4 | 37/29 | 64.9/50.6 | 0.2924 |  |  |
Lymph node metastasis, − / +  | 27/39 | 69.7/51.3 | 0.0112 | 0.43 (0.195–0.909) | 0.0265 |
KRAS mutation, Wild/Mutant | 11/18 | 55.6/45.5 | 0.6377 | Â | Â |
Adjuvant chemotherapy after primary surgery, − / +  | 56/10 | 60.2/50.0 | 0.3630 |  |  |
Timing of liver metastasis, Synchronous/metachronous | 27/39 | 53.9/65.8 | 0.2591 | Â | Â |
Metastasis other than liver, − / +  | 54/12 | 62.5/41.7 | 0.1181 |  |  |
Number of liver metastasis, Solitary/Multiple | 23/43 | 69.1/53.5 | 0.1929 | Â | Â |
Size of largest tumor (cm), < 5/ ≥ 5 | 53/13 | 65.6/46.2 | 0.3057 |  |  |
Hepatectomy, Minor/Major | 56/10 | 62.6/40.0 | 0.0687 | Â | Â |
Surgical margin, R0/R1,R2 | 35/31 | 67.9/48.4 | 0.0287 | 0.49 (0.241–0.972) | 0.0410 |
H factor, H1/H2-H3 | 43/23 | 71.6/34.8 | 0.0171 | 0.70 (0.327–1.548) | 0.3713 |
Expression of Smurf 2 in primary tumor, High/Low | 31/35 | 71.0/47.6 | 0.0265 | 0.47 (0.232–0.957) | 0.0370 |
